Basket | Login



Diagnosis and treatment of dementia

  1. Iliffe S, Robinson L, Brayne C, Goodman C, Rait G, Manthorpe J et al. Primary care and dementia: 1. diagnosis, screening and disclosure. Int J Geriatr Psychiatry 2009 February 18.
  2. Martin AJ, Marottoli R, O'Neill D. Driving assessment for maintaining mobility and safety in drivers with dementia. Cochrane Database Syst Rev 2009;(1):CD006222.
  3. Okonkwo OC, Wadley VG, Griffith HR, Belue K, Lanza S, Zamrini EY et al. Awareness of deficits in financial abilities in patients with mild cognitive impairment: going beyond self-informant discrepancy. Am J Geriatr Psychiatry 2008 August;16(8):650-9.
  4. Lai JM, Karlawish J. Assessing the capacity to make everyday decisions: a guide for clinicians and an agenda for future research. Am J Geriatr Psychiatry 2007 February;15(2):101-11.
  5. Brayne C, Fox C, Boustani M. Dementia screening in primary care: is it time? JAMA 2007 November 28;298(20):2409-11.
  6. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for Dementia in Primary Care. Summary of the Evidence. 2003.
  7. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003 June 3;138(11):927-37.
  8. Wedderburn C, Wear H, Brown J, Mason SJ, Barker RA, Hodges J et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008 May;79(5):500-3.
  9. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992 September;40(9):922-35.
  10. Milne A, Culverwell A, Guss R, Tuppen J, Whelton R. Screening for dementia in primary care: a review of the use, efficacy and quality of measures. Int Psychogeriatr 2008 October;20(5):911-26.
  11. Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry 2007 August;78(8):790-9.
  12. Brodaty H, Low LF, Gibson L, Burns K. What is the best dementia screening instrument for general practitioners to use? Am J Geriatr Psychiatry 2006 May;14(5):391-400.
  13. Cherbuin N, Anstey KJ, Lipnicki DM. Screening for dementia: a review of self- and informant-assessment instruments. Int Psychogeriatr 2008 June;20(3):431-58.
  14. Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. Can J Psychiatry 2002 October;47(8):723-33.
  15. Holsinger T, Deveau J, Boustani M, Williams JW, Jr. Does this patient have dementia? JAMA 2007 June 6;297(21):2391-404.
  16. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement 2008 November;4(6):428-37.
  17. Brodaty H, Kemp NM, Low LF. Characteristics of the GPCOG, a screening tool for cognitive impairment. Int J Geriatr Psychiatry 2004 September;19(9):870-4.
  18. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K et al. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002 March;50(3):530-4.
  19. Shulman KI, Herrmann N, Brodaty H, Chiu H, Lawlor B, Ritchie K et al. IPA survey of brief cognitive screening instruments. Int Psychogeriatr 2006 June;18(2):281-94.
  20. Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000 June;15(6):548-61.
  21. Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 1998 May;64(5):588-94.
  22. Royall DR, Mulroy AR, Chiodo LK, Polk MJ. Clock drawing is sensitive to executive control: a comparison of six methods. J Gerontol B Psychol Sci Soc Sci 1999 September;54(5):328-33.
  23. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM et al. Screening for dementia with the memory impairment screen. Neurology 1999 January 15;52(2):231-8.
  24. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004 September;16(3):275-93.
  25. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology 2006 December 12;67(11):1942-8.
  26. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E et al. The AD8: a brief informant interview to detect dementia. Neurology 2005 August 23;65(4):559-64.
  27. Galvin JE, Roe CM, Coats MA, Morris JC. Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol 2007 May;64(5):725-30.
  28. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005 April;53(4):695-9.
  29. Meulen EF, Schmand B, van Campen JP, de Koning SJ, Ponds RW, Scheltens P et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004 May;75(5):700-5.
  30. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004 February;19(2):136-43.
  31. Williams JG, Huppert FA, Matthews FE, Nickson J. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. Int J Geriatr Psychiatry 2003 July;18(7):631-44.
  32. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000 December 12;55(11):1613-20.
  33. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998 June;20(3):310-9.
  34. Hentschel F, Kreis M, Damian M, Krumm B, Frolich L. The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. Int J Geriatr Psychiatry 2005 July;20(7):645-50.
  35. Scheltens P, Fox N, Barkhof F, De CC. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002 May;1(1):13-21.
  36. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003 February;18(2):525-41.
  37. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003 August;34(8):1907-12.
  38. Dougall N, Nobili F, Ebmeier KP. Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 2004 July 30;131(2):157-68.
  39. O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009 January;194(1):34-9.
  40. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001 November 7;286(17):2120-7.
  41. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009 February;30(2):404-10.
  42. Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007 August 28;69(9):871-7.
  43. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008 October;29(10):1456-65.
  44. Robinson DJ, Merskey H, Blume WT, Fry R, Williamson PC, Hachinski VC. Electroencephalography as an aid in the exclusion of Alzheimer's disease. Arch Neurol 1994 March;51(3):280-4.
  45. Claus JJ, Strijers RL, Jonkman EJ, Ongerboer d, V, Jonker C, Walstra GJ et al. The diagnostic value of electroencephalography in mild senile Alzheimer's disease. Clin Neurophysiol 1999 May;110(5):825-32.
  46. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008 March;131(Pt 3):690-705.
  47. Zerr I, Schulz-Schaeffer WJ, Giese A, Bodemer M, Schroter A, Henkel K et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol 2000 September;48(3):323-9.
  48. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004 June 26;363(9427):2105-15.
  49. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008 March;69(3):341-8.
  50. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008 November 19;300(19):2253-62.
  51. Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007;(2):CD003120.
  52. Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 2003;29(1):57-72.
  53. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007 November;15(11):942-52.



Last Updated: Thursday 08 October 2009


  • Acknowledgements

    The EuroCoDe project received financial support from the European Commission. Neither the European Commission nor any person acting on its behalf is responsible for any use that might be made of the following information. Alzheimer Europe also gratefully acknowledges the support it received from Fondation Médéric Alzheimer for this project.
  • European Union
  • Fondation Médéric Alzheimer